Hologic reported first quarter fiscal 2026 results with revenue of $1.047 billion, representing a 2.5% year-over-year increase. However, the company missed analyst expectations, with earnings per share of $1.04 on a non-GAAP basis falling short of the Zacks Consensus Estimate of $1.09. GAAP diluted EPS decreased 9.2% to $0.79. Gross margin declined 150 basis points during the quarter, driven by weakness in the Diagnostics segment, which was partially offset by strong growth in GYN Surgical. The stock declined following the earnings announcement. Additionally, Hologic announced a special stockholder meeting scheduled for February 5, 2026, to vote on a merger agreement with funds managed by Blackstone and TPG.
Read full analysisHologic reported first quarter fiscal 2026 results with revenue of $1.047 billion, representing a 2.5% year-over-year increase. However, the company missed analyst expectations, with earnings per share of $1.04 on a non-GAAP basis falling short of the Zacks Consensus Estimate of $1.09. GAAP diluted EPS decreased 9.2% to $0.79. Gross margin declined 150 basis points during the quarter, driven by weakness in the Diagnostics segment, which was partially offset by strong growth in GYN Surgical. The stock declined following the earnings announcement. Additionally, Hologic announced a special stockholder meeting scheduled for February 5, 2026, to vote on a merger agreement with funds managed by Blackstone and TPG.
Hologic Inc. (HOLX) is a publicly traded company in the Healthcare sector.